# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

# APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State of Incorporation)

46-3837784

(I.R.S. Employer Identification No.)

700 North Brand Boulevard
Suite 1400
Glendale, California 91203
(Address of principal executive offices)

Apollo Medical Holdings, Inc. 2010 Equity Incentive Plan Apollo Medical Holdings, Inc. 2015 Equity Incentive Plan (Full titles of the plan)

Warren Hosseinion, M.D.
President and Chief Executive Officer
Apollo Medical Holdings, Inc.
700 North Brand Boulevard, Suite 1400
Glendale, California 91203
(818) 396-8050

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Lance Jon Kimmel SEC Law Firm 11693 San Vicente Boulevard, Suite 357 Los Angeles, California 90049 (310) 207-0665

ndicate by check mark wheth	er the registrant is a larg	e accelerated filer, ar	n accelerated filer, a non-a	ccelerated filer, a smal	ler reporting company, of	or an emerging growth
company. See definitions of "l	arge accelerated filer," "	'accelerated filer", "s	smaller reporting company	" and "emerging grow	th company" in Rule 12	b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐

Non-accelerated filer ☐ Emerging growth company ☐ (Do not check if a smaller reporting company)

Smaller reporting company ⊠

### CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share(2)	Proposed Maximum Aggregate Offering Price(3)	Amount of Registration Fee
Common Stock (par value \$0.001)	2,497,500(2) \$	9.825 \$	24,537,937 \$	2,843.95

- (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Act"), this Registration Statement shall cover any additional shares of Common Stock that become issuable under the Registrant's 2010 Equity Incentive Plan (the "2010 Plan") and/or 2015 Equity Incentive Plan (the "2015 Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction without receipt of consideration which results in an increase in the number of shares of the Registrant's outstanding Common Stock.
- (2) Consists of (i) 307,500 shares issuable under the 2010 Plan (after giving effect to a 1-for-10 reverse stock split effected on April 24, 2015 (the "reverse stock split")); (ii) 1,500,000 shares issuable under the 2015 Plan; and (iii) 690,000 additional shares issuable under the 2015 Plan that became available for grant thereunder due to the expiration of grants under the 2010 Plan and the 2013 Equity Incentive Plan (after giving effect to the reverse stock split).
- (3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Act. The offering price per share and aggregate offering price are based on the average of the high and low prices of the Registrant's Common Stock as reported on the OTC Pink on May 2, 2017.

#### PART I

## INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

#### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.

The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

- The Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2016, filed with the Commission on June 29, 2016;
- The Company's Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the Commission on August 15, 2016;
- The Company's Quarterly Report on Form 10-Q for the period ended September 30, 2016, filed with the Commission on November 14, 2016;
- The Company's Quarterly Report on Form 10-Q for the period ended December 30, 2016, filed with the Commission on February 14, 2017;
- The Company's Current Reports on Form 8-K, filed with the Commission on April 4, 2016, June 28, 2016, July 26, 2016, September 16, 2016, November 10, 2016, November 29, 2016, December 22, 2016, December 22, 2016, January 20, 2017, February 13, 2017, April 5, 2017 and April 28, 2017;
- The Company's Proxy Statement on Schedule 14A, filed with the Commission on July 29, 2016; and
- The description of the Company's Common Stock contained in the Company's registration statement on Form 8-A filed with the Commission on May 14, 2015, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

#### Item 4. Description of Securities.

Not applicable.

## Item 5. Interests of Named Experts and Counsel.

Not applicable.

#### Item 6. Indemnification of Directors and Officers.

As permitted by Delaware law, the Company's restated certificate of incorporation (the "Certificate of Incorporation") provides for broad indemnification of its directors and officers. Specifically, to the fullest extent permitted by the Delaware General Corporation Law, as it presently exists or may hereafter amended from time to time (the "DGCL"), a director of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director. Neither any amendment to, modification of, nor repeal of the Certificate of Incorporation, nor the adoption of any provision of the Certificate of Incorporation shall (i) eliminate, or reduce the effect of this provision in respect of any matter occurring, or any cause of action, suit or proceeding accruing or arising or that, but for this provision, would accrue or arise, prior to such amendment, modification, repeal or adoption of an inconsistent provision; or (ii) eliminate, reduce or otherwise adversely affect any right or protection of a current or former director of the Company existing at the time of such amendment, modification, repeal or adoption. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company or its stockholders shall be eliminated or limited to the fullest extent permitted by the DGCL.

Each person who was or is a party or is made a party, threatened to be made a party or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a "proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer of the Company or is or was serving at the request of the Company as a director, a member of any committee of the Board of Directors, or an officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (hereinafter an "indemnitee"), whether the basis of such proceeding is alleged action in an official capacity as a director, committee member, officer or representative or in any other capacity while serving as a director, committee member, officer or representative, shall be indemnified and held harmless by the Company, to the fullest extent permitted by the DGCL, against all expenses, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith and such indemnification will continue as to an indemnitee who has ceased to be a director, committee member, officer or representative and shall inure to the benefit of his or her heirs, executors and administrators. Such right shall be a contract right and shall include the right to be paid by the Company the expenses incurred in defending any such proceeding in advance of its final disposition (hereinafter an "advancement"); provided, however, if the DGCL requires, such advancement shall be made only upon delivery to the Company of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled

Additionally, the Company's restated Bylaws provide that the Company shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. To the extent that a director, officer, employee or agent of the Company has been successful on the merits or otherwise in defense of any action, suit or proceeding, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorney's fees) actually and reasonably incurred by him in connection therewith. Expenses incurred in defending a civil or criminal action, suit or proceeding may be paid in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of the director, officer, employee or agent to repay such amount unless it shall ultimately be determined that he is entitled to be indemnified by the Company. Notwithstanding the foregoing, there shall not be any indemnification of a director or officer if such indemnification is for any reason contrary to law, either as a matter of public policy, or under the provisions of the Securities Act of 1933, the Securitie

Moreover, the Company and each director have entered into an indemnification agreement, which are substantively identical to each other. The indemnification agreements require the Company to indemnify these individuals against expenses, witness fees, damages, judgments, fines and settlement amounts incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these individuals may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Registrant or is or was serving or at any time serves at the request of the Registrant as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

The Company currently carries liability insurance for its directors and officers.

Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission, such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

## Item 7. Exemption from Registration Claimed.

Not Applicable.

Item 8. Exhibits.

Exhibit Number	
4.1(1)	Restated Certificate of Incorporation
4.2(2)	Certificate of Amendment to Restated Certificate of Incorporation
4.3(3)	Certificate of Designation of Series A Convertible Preferred Stock
4.4(4)	Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc.
4.5(5)	Restated Bylaws
4.6*	Form of Common Stock Certificate
5.1*	Opinion of SEC Law Firm
23.1*	Consent of Independent Registered Public Accounting Firm
23.2*	Consent of SEC Law Firm (contained in Exhibit 5.1 to this Registration Statement)
24.1*	Power of Attorney (contained on the signature pages to this Registration Statement)
99.1(6)	2010 Equity Incentive Plan
99.2(7)	2015 Equity Incentive Plan

<sup>\*</sup> filed herewith

- (1) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 21, 2015.
- (2) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 27, 2015.
- (3) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 19, 2015.
- (4) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 4, 2016.
- (5) Incorporated by reference from an exhibit to the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 16, 2015.
- (6) Incorporated by reference from Appendix A to Information Statement on Schedule 14C, filed with the Securities and Exchange Commission on August 17, 2010.
- (7) Incorporated by reference from an exhibit to the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on June 29, 2016.

## Item 9. <u>Undertakings</u>

#### A. The undersigned Registrant hereby undertakes:

- 1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
- (i) To include any prospectus required by section 10(a)(3) of the Securities Act;
- (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement.
- (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

- 2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  - 3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Glendale, State of California, on May 5, 2017.

## APOLLO MEDICAL HOLDINGS, INC.

By: /s/ Warren Hosseinion
Warren Hosseinion
President and Chief Executive Officer

# POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Warren Hosseinion and Gary Augusta, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the "SEC"), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date	
/s/ Warren Hosseinion Warren Hosseinion	President, Chief Executive Officer and Director (Principal Executive Officer)	May 5, 2017	
/s/ Mihir Shah Mihir Shah	Chief Financial Officer (Principal Financial and Accounting Officer)	May 5, 2017	
/s/ Gary Augusta Gary Augusta	Chairman of the Board of Directors	May 5, 2017	
/s/ Mark Fawcet Mark Fawcett	Director	May 5, 2017	
/s/ Thomas Lam Thomas Lam	Director	May 5, 2017	
/s/ Suresh Nihalani Suresh Nihalani	Director	May 5, 2017	
/s/ David Schmidt David Schmidt	Director	May 5, 2017	
/s/ Ted Schreck Ted Schreck	Director	May 5, 2017	
	7		

#### EXHIBIT INDEX

## Number 4.1(1) Restated Certificate of Incorporation Certificate of Amendment to Restated Certificate of Incorporation 4.2(2)Certificate of Designation of Series A Convertible Preferred Stock 4.3(3)4.4(4) Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. 4.5(5)Restated Bylaws 4.6\* Form of Common Stock Certificate 5.1\* Opinion of SEC Law Firm 23.1\* Consent of Independent Registered Public Accounting Firm 23.2\* Consent of SEC Law Firm (contained in Exhibit 5.1 to this Registration Statement) 24.1\* Power of Attorney (contained on the signature pages to this Registration Statement) 99.1(6) 2010 Equity Incentive Plan 99.2(7) 2015 Equity Incentive Plan

## \* filed herewith

Exhibit

- (1) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 21, 2015.
- (2) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 27, 2015.
- (3) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 19, 2015.
- (4) Incorporated by reference from an exhibit to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 4, 2016.
- (5) Incorporated by reference from an exhibit to the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 16, 2015.
- (6) Incorporated by reference from Appendix A to Information Statement on Schedule 14C, filed with the Securities and Exchange Commission on August 17, 2010.
- (7) Incorporated by reference from an exhibit to the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on June 29, 2016.



# apollomed

APOLLO MEDICAL HOLDINGS, INC.



THIS THAT

The Record Holds Of

Shars of APOLLO MEDICAL HOLDINGS, INC. Common Stock trusterable in the book of the Corporation in person or by duly authorized attorney upon surrender of the Certificate roperly endorsed. This Certificate is not valid until countersigned by the Transfer Agent an expected by the Registrar.

Witness the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers.

Dated:

Warm Hossecman

SPORETARY

Seal

OTC STOCK TRANSFER INC. SALT LAKE CITY, UTAH

COUNTERSIGNED & REGISTERED

COUNTERSIGNED Transfer Agent-Authorized Signature



www.seclawfirm.com

11693 San Vicente Boulevard Suite 357 Los Angeles, California 90049 310-207-0665

Writer's direct dial: 310-557-3059

May 5, 2017

Apollo Medical Holdings, Inc. 700 North Brand Boulevard. Suite 1400 Glendale, California 91203

Re: Apollo Medical Holdings, Inc. Registration Statement on Form S-8

#### Ladies and Gentlemen:

We have acted as counsel for Apollo Medical Holdings, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of the Company's Registration Statement on Form S-8 (the "Registration Statement"), under the Securities Act of 1933, as amended (the "Securities Act"), relating to the registration of an aggregate of 2,497,500 shares of the Company's common stock, par value \$0.001 per share (the "Shares"), reserved for issuance pursuant to the Company's 2010 Equity Incentive Plan and 2015 Equity Incentive Plan (collectively, the "Plans"). As your legal counsel, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans.

In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Restated Certificate of Incorporation of the Company, (ii) the Restated Bylaws of the Company, (iii) the Registration Statement, (iv) the Plans, and (v) such corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company, and have made such inquiries of such officers and representatives, as we have deemed relevant and necessary or appropriate as a basis for the opinion set forth below.

In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic, certified or photostatic copies, and the authenticity of the originals of such copies. In making our examination of documents executed or to be executed, we have assumed that the parties thereto, other than the Company, had or will have the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or other, and the execution and delivery by such parties of such documents and the validity and binding effect thereof on such parties. As to any facts material to the opinions expressed herein that we did not independently establish or verify, we have relied upon statements and representations of officiers and other representatives of the Company and others and of public

Based on the foregoing and subject to the limitations, qualifications and assumptions set forth herein, we are of the opinion that the Shares to be issued pursuant to the terms of the respective Plans have been duly authorized and, when issued, delivered and paid for in accordance with the terms of the respective Plans, will be validly issued, fully paid and non-assessable.

Apollo Medical Holdings, Inc. May 5, 2017 Page Two

The opinion expressed herein is limited to the corporate laws of the State of Delaware and the federal laws of the United States of America, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdictions.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not hereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Lance Jon Kimmel

Lance Jon Kimmel

SEC LAW FIRM 11693 San Vicente Boulevard, Suite 357 Los Angeles, CA 90049 Tel. 310-207-0665 Fax. 310-388-1320 www.seclawfirm.com

# Consent of Independent Registered Public Accounting Firm

Apollo Medical Holdings, Inc. Glendale, California

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated June 29, 2016, relating to the consolidated financial statements of Apollo Medical Holdings, Inc. (the "Company") appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2016.

/s/ BDO USA, LLP

Los Angeles, California May 5, 2017